LABU241213C134000
- 0.01
- -0.17-94.44%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Neurocrine Wins FDA Nod for CAH Therapy
Weekly Buzz: Tech stocks hit high scores on ominous day
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Market Mixed on Friday the 13th | Livestock
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Natera Analyst Ratings
Gilead Sciences Says Committee For Medicinal Products For Human Use Of European Medicines Agency Recommends Seladelpar For Treatment Of Primary Biliary Cholangitis In Combination With Ursodeoxycholic Acid (UDCA) In Adults With Inadequate Response To...
Thursday Ends in Index Declines | Wall Street Today
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites
$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
10 Health Care Stocks With Whale Alerts In Today's Session
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Incyte's Late-Breaking ASH 2024 Data Show Tafasitamab (Monjuvi) Significantly Improves Progression-Free Survival In Relapsed/Refractory Follicular Lymphoma, Meeting Phase 3 InMIND Trial Endpoints; U.S. SBLA Filing Planned By Year-End 2024
B of A Securities Reinstates Buy on Gilead Sciences, Announces $109 Price Target